|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001675,
umls-concept:C0012634,
umls-concept:C0035236,
umls-concept:C0036043,
umls-concept:C0042210,
umls-concept:C0205265,
umls-concept:C0220825,
umls-concept:C0600688,
umls-concept:C1516634,
umls-concept:C1527148,
umls-concept:C1555582,
umls-concept:C1709630,
umls-concept:C2349975
|
|
pubmed:issue |
50
|
|
pubmed:dateCreated |
2008-11-17
|
|
pubmed:abstractText |
MEDI-534 is a bivalent live attenuated vaccine candidate against human respiratory syncytial virus (hRSV) and human parainfluenza virus type 3 (hPIV3) that was previously shown to be immunogenic and to protect rodents and African green monkeys from wild-type (wt) hRSV challenge. We performed further preclinical evaluations to address the safety of MEDI-534 prior to human testing. MEDI-534 did not predispose rodents to enhanced RSV disease following wt-RSV challenge, and the tissue tropism of the chimeric virus was confined to the respiratory tract. Representative clinical trial material did not produce toxicity in rats. In adults, MEDI-534 was highly restricted in replication, did not boost RSV and PIV3 antibody titers, and produced no medically significant vaccine-related adverse events thereby warranting further evaluation in pediatric populations.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0264-410X
|
|
pubmed:author |
pubmed-author:ChandlerPatriciaP,
pubmed-author:GomezMargarita MMM,
pubmed-author:GuzzettaJeanne MJM,
pubmed-author:HiltyMiloM,
pubmed-author:LosonskyGenevieve AGA,
pubmed-author:MacPhailMiaM,
pubmed-author:ReisingerKeithK,
pubmed-author:RyanPatricia CPC,
pubmed-author:SpaeteRichard RRR,
pubmed-author:TangRoderick SRS,
pubmed-author:ThompsonMark WMW,
pubmed-author:WalkerRobert ERE
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
25
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6373-82
|
|
pubmed:meshHeading |
pubmed-meshheading:18822334-Adolescent,
pubmed-meshheading:18822334-Adult,
pubmed-meshheading:18822334-Animals,
pubmed-meshheading:18822334-Cercopithecus aethiops,
pubmed-meshheading:18822334-Cricetinae,
pubmed-meshheading:18822334-Disease Models, Animal,
pubmed-meshheading:18822334-Double-Blind Method,
pubmed-meshheading:18822334-Female,
pubmed-meshheading:18822334-Genetic Vectors,
pubmed-meshheading:18822334-Humans,
pubmed-meshheading:18822334-Male,
pubmed-meshheading:18822334-Parainfluenza Vaccines,
pubmed-meshheading:18822334-Parainfluenza Virus 3, Human,
pubmed-meshheading:18822334-Rats,
pubmed-meshheading:18822334-Rats, Sprague-Dawley,
pubmed-meshheading:18822334-Respiratory Syncytial Virus, Human,
pubmed-meshheading:18822334-Respiratory Syncytial Virus Infections,
pubmed-meshheading:18822334-Respiratory Syncytial Virus Vaccines,
pubmed-meshheading:18822334-Respirovirus Infections,
pubmed-meshheading:18822334-Sigmodontinae,
pubmed-meshheading:18822334-Treatment Outcome,
pubmed-meshheading:18822334-Vaccines, Attenuated,
pubmed-meshheading:18822334-Vero Cells,
pubmed-meshheading:18822334-Young Adult
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.
|
|
pubmed:affiliation |
MedImmune, 297 North Bernardo Avenue, Mountain View, CA 94043, USA. tangr@medimmune.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
